sahmcapital.com
Cure8 news brief
Why This Matters
A new investigational drug (EOM613) is entering a small Phase II trial for Crohn’s disease, which could become a future treatment option if later studies are positive. Early-stage industry updates can indicate where research and trial opportunities may appear.
Who Should Pay Attention
Patients with Crohn’s disease interested in clinical trials, clinical researchers tracking emerging therapies, and clinicians who follow experimental drug development.
Study Snapshot
Story typeBusiness news
Evidence typePhase 2 clinical trial
Source depthFull source text
What To Know
EOM Pharmaceutical says it completed preclinical IND-enabling studies for EOM613 and plans a small Phase II exploratory trial in Crohn’s disease to start in Q1 2026, enrolling about 15–20 patients at sites in New Jersey.
The company also mentions prior Phase I/IIa data in hospitalized COVID-19 patients and separate development plans for EOM613 in cancer cachexia and for other assets (EOM147) in ocular diseases. This appears to be an industry news brief summarizing the company’s development plans rather than a peer-reviewed study report.
It does not include clinical results or details on dosing, endpoints, or mechanism of action for Crohn’s disease. If you want more detail, look for the company’s original press release or clinicaltrials.gov listings for the planned Phase II trial for enrollment criteria, endpoints, and timing.
Keep In Mind
This is an early-stage company announcement and not a clinical result. Phase II here is exploratory with a small planned sample (15–20 patients); such trials are intended to assess signals of activity and safety, not to establish efficacy.
The brief was generated from company content and a third-party AI summary—refer to the original company materials or trial registry for authoritative details.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationsahmcapital.com
Indexed viaGoogle News
Source typeBusiness news
PublishedMar 25, 2026, 10:16 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Teva, Sanofi present new results from RELIEVE UCCD Phase 2b study
New Phase 2b data were presented for duvakitug, an investigational antibody for UC and Crohn’s disease; people with IBD may see this as a potential future treatment option if later trials are positive. The report focuses...
Crohn's Disease Clinical Trials And Studies 2025: EMA, PDMA, FDA Approvals, Mechanism ...
This roundup highlights many drugs and trials in development for Crohn’s disease, including late‑stage studies of biologics and newer oral agents — information that could affect future treatment options. Patients on...
RedHill Biopharma announces plans to advance program for Crohn's disease
This reports a company moving a MAP-targeted antibiotic-like therapy (RHB-204, related to RHB-104) into a Phase 2 trial for Crohn’s disease with mucosal healing and MAP eradication as key endpoints—topics that could...